AstraZeneca plc (LON:AZN)’s share price traded up 2.1% during trading on Monday . The company traded as high as GBX 5,068 ($67.22) and last traded at GBX 5,061 ($67.13). 2,453,236 shares were traded during trading, an increase of 6% from the average session volume of 2,304,000 shares. The stock had previously closed at GBX 4,955 ($65.72).

Several equities analysts have weighed in on AZN shares. UBS AG set a GBX 5,150 ($68.31) target price on shares of AstraZeneca plc and gave the company a “neutral” rating in a report on Tuesday, June 27th. J P Morgan Chase & Co restated a “neutral” rating on shares of AstraZeneca plc in a report on Thursday, July 13th. Credit Suisse Group reduced their price target on shares of AstraZeneca plc from GBX 5,000 ($66.32) to GBX 4,700 ($62.34) and set a “neutral” rating on the stock in a research report on Friday, July 28th. Goldman Sachs Group, Inc. (The) set a GBX 3,900 ($51.73) price target on shares of AstraZeneca plc and gave the company a “sell” rating in a research report on Wednesday, August 2nd. Finally, Shore Capital reiterated a “hold” rating on shares of AstraZeneca plc in a report on Wednesday, August 2nd. Three equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and eleven have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of GBX 5,111.27 ($67.80).

The company has a 50-day moving average of GBX 4,692.03 and a 200-day moving average of GBX 4,893.11. The stock’s market capitalization is GBX 64.52 billion.

The business also recently announced a dividend, which was paid on Monday, September 11th. Investors of record on Thursday, August 10th were issued a GBX 68.90 ($0.91) dividend. The ex-dividend date was Thursday, August 10th. This represents a yield of 1.35%.

In related news, insider Nazneen Rahman purchased 39 shares of the business’s stock in a transaction on Thursday, July 27th. The shares were bought at an average price of GBX 4,370 ($57.97) per share, with a total value of £1,704.30 ($2,260.64).

COPYRIGHT VIOLATION NOTICE: “AstraZeneca plc (AZN) Stock Price Up 2.1%” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.thecerbatgem.com/2017/10/04/astrazeneca-plc-azn-stock-price-up-2-1.html.

AstraZeneca plc Company Profile

AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.

Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.